RE: Buy out prediction in Proactive Investors11 Jul 2021 11:57
@Genki
I doubt very much he would tbh.
The reason for this is that the Genedrive POC unit has such huge potential in almost every setting.
I am not sure that many of the readers of this board quiet understand how amazing it is. This is a tried and tested POC testing unit which at the moment has a small number (but rapidly growing) number of tests. There is 20 years worth of development in this device it has proven to be amazingly accurate and simple to use and adaptable to many different environments. There are quiet literally tens of thousands of hospital tests which could eventually be run on it. It is highly suitable for use in many different settings from Health centres, Nursing homes, Doctors surgery's, Hospitals, to battle fields and emergency crisis situations and it is ideally suited for testing isolated rural communities. It can very easily adapted and tailored to any of these situations and is so easy to use the hardest part of its operation is taking the sample from the patient, The results are clear and simple to read and it is amazingly accurate. The time in R&D and the trials and product evaluation particularly by the US DoD. testing it has gone through have ironed out many of the potential issues and added design features at almost every stage. More importantly it has been shown to be reliable. It is streets ahead of most of its competition. Then there are the areas which have not even yet been considered for development, farming for example a test for Bovine TB which can be done on site in 20 minutes on site could save farmers weeks of waiting for results and give them the ability to isolate individual animals or small groups instead of whole herds which has a huge economic impact. Research is another area this product used already in (i can't remember what but it had to do with prawns). So that is just the POC platform.
The advantages of each test has been gone over and over on here but the hearing loss test (@myluck, That is the test which tells a doctor if a child has a genetic make up which would cause it to loose its hearing if given a common antibiotic) (not a ****ing hearing aid) should be mentioned when considering what DB would consider a good price for GDR. In the trials that test saved the hearing of 2 children, 2 children are now still able to hear because of GDR, not sure how you value that. This is quiet obviously the test which DB is proudest of just look at any of the presentations. I can't remember what the UK/ per year value he estimated but it has to be around 30 to £40M again i have no idea how much that converts to Market cap but considering NCYT had a single order of £90M (not a yearly recurring income) and it reached the levels it did the £250Mish your suggesting seams a touch low to me (just my opinion). That is not counting the USA which as I have pointed out many times and DB noted in his last presentation is litigation heavy (if a baby losses its hearing and there is a test available....
Sign In
Follow the stocks
